Last reviewed · How we verify
Palbociclib tablet
At a glance
| Generic name | Palbociclib tablet |
|---|---|
| Also known as | Ibrance® |
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma (PHASE2)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- SNV4818 in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease (PHASE3)
- A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer (PHASE1)
- Study of INCB123667 in Subjects With Advanced Solid Tumors (PHASE1)
- Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer (PHASE3)
- Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Palbociclib tablet CI brief — competitive landscape report
- Palbociclib tablet updates RSS · CI watch RSS
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. portfolio CI